» Articles » PMID: 24337058

[Interval for Access to Treatment for Breast Cancer in the Federal District, Brazil]

Overview
Date 2013 Dec 17
PMID 24337058
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze the time between the first symptom and treatment in patients treated for breast cancer in public hospitals in the Federal District.

Methods: This was a cross-sectional analysis. We interviewed 250 women diagnosed with breast cancer treated in six hospitals of the State Department of Health of the Federal District from November 2009 to January 2011. The time intervals studied were the time between the detection of the symptoms and treatment subdivided into intervals until and after the first medical appointment. The variables were: age, menopausal status, color, educational level, average monthly household income, origin, reason for the initial consultation, staging, tumor size, laterality, metastasis to axillary lymph nodes, neoadjuvant chemotherapy, and type of surgery. The Mann-Whtney test was used to assess the association of these variables with the time intervals until treatment.

Results: The mean age was 52 years, with a predominance of white women (57.6%), from the Federal District (62.4%), with a family income of up to 2 minimum wages (78%), and up to four years of schooling (52.4%). The staging of the disease ranged from II to IV in 78.8% of the women. The time between the first symptom and treatment was 229 days (median). After detection of the first symptom, 52.9% of the women attended a consultation within 30 days and 88.8% took more than 90 days to start treatment. Women with elementary school education had a greater delay to the start of treatment (p=0.049).

Conclusions: There was a significant delay to start treatment of women with breast cancer in public hospitals of the Federal District, suggesting that efforts should be made to reduce the time needed to schedule medical appointments and to diagnose and treat these patients.

Citing Articles

Delayed breast cancer presentation, diagnosis, and treatment in Kenya.

Daniel O, Ashrafi A, Muthoni M, Njoki N, Eric H, Marilynn O Breast Cancer Res Treat. 2023; 202(3):515-527.

PMID: 37668821 PMC: 11906215. DOI: 10.1007/s10549-023-07067-y.


Shorter delay to treatment by integrated diagnostic services and NGO-provided support among breast cancer patients in two Brazilian referral centres.

Dos Santos Andrade L, Santos T, Edite Case de Oliveira M, Gomes K, Araujo Pereira Soares A, Oliveira T J Public Health Res. 2021; 10(3).

PMID: 33709643 PMC: 8314677. DOI: 10.4081/jphr.2021.1880.


Analysis of the Immunoexpression of Opioid Receptors and their Correlation with Markers of Angiogenesis, Cell Proliferation and Apoptosis in Breast Cancer.

de Sousa A, Dantas T, Barros Silva P, Martins C, Freire G, Ribeiro Junior H Asian Pac J Cancer Prev. 2021; 22(2):633-640.

PMID: 33639684 PMC: 8190334. DOI: 10.31557/APJCP.2021.22.2.633.


Availability of Diagnostic Services and their Impact on Patient Flow in Two Brazilian Referral Centres of Breast Cancer Treatment.

Santos T, Dos Santos Andrade L, Edite Case de Oliveira M, Gomes K, Oliveira T, Weller M Asian Pac J Cancer Prev. 2020; 21(2):317-324.

PMID: 32102505 PMC: 7332143. DOI: 10.31557/APJCP.2020.21.2.317.


Realizing the right to health in Brazil's Unified Health System through the lens of breast and cervical cancer.

da Mota Almeida Peroni F, Lindelow M, Oliveira De Souza D, Sjoblom M Int J Equity Health. 2019; 18(1):39.

PMID: 31155002 PMC: 6545675. DOI: 10.1186/s12939-019-0938-x.